GenomeDx Biosciences bagged Medicare coverage for its postoperative prostate cancer diagnostic, putting its test in the hands of more patients and helping the company gain ground in a crowded market.
Prostate cancer diagnostic research is taking interesting new steps toward personalized medicine in two separate projects, both involving The University of Texas MD Anderson Cancer Center.
Researchers from the U.K. and Italy have figured out two things that could improve both the diagnosis and ongoing treatment of advanced prostate cancer.
Just over a month after striking an immunotherapy pact with AstraZeneca, New Jersey biotech Advaxis is back with another Big Pharma agreement. This time, the company will be teaming up with Merck to test its cancer vaccine, ADXS-PSA, in combination with the latter's checkpoint inhibitor pembrolizumab.
The FDA's Gastroenterology & Urology Devices panel came down firmly against EDAP's Ablatherm system for treating low-risk, localized prostate cancer. The panel voted 9-0 on the device's effectiveness, 5-3 against its safety (with one abstention) and said the risks outweigh the benefits by a vote of 8-0 (with one abstention).
French devicemaker EDAP TMS SA is facing FDA scrutiny for its robotic device for prostate cancer, as regulators questioned the product's safety and efficacy in a new report.
The cancer vaccine field has seen its share of late-stage disappointments and outright flops, but a number of hopefuls are lining up to present new research backing their experimental shots at this year's upcoming American Society of Clinical Oncology Annual Meeting in Chicago.
As Astellas Pharma and Medivation work to broaden the reach of their prostate cancer drug Xtandi, researchers have identified a biomarker that could help proactively spot patients for whom the treatment will not work.
MDxHealth will ally with a Texas-based provider network in a deal that will greatly expand the reach of its signature prostate cancer molecular diagnostic test to millions of additional patients.
New research supports the use of a circulating tumor cell blood test, rather than the standard PSA biomarker diagnostic, to predict a patient's odds of surviving prostate cancer.